Trial Profile
A study investigating the effect of fingolimod [Gilenya] on sub-cortical structures volumes and cortical thickness in patients with relapsing-remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2015
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 21 Dec 2015 New trial record